title: Future approaches for treating hematologic disease.
abstract: The approval of monoclonal antibodies for therapy of hematologic malignacies (Rituxan, Mylotarg, Campath) renewed the interest in antibodies as potential new treatment options for cancer patients. Antibodies are effective in inhibiting tumor cell growth , inducing apoptosis, and activating host effector mechanisms for tumor cell killing. Monoclonal antibodies can be clinically effective as monotherapy, as targeting agents delivering either potent cytotoxic drugs or radionuclides as well as in combination with conventional chemotherapies. Advances in antibody engineering provided new capabilities to reduce immunogenicity, alter half life, increase effector functions, and increase tumor targeting for optimal therapeutic modalities requiring chronic dosing regimens. During the next decade, as new tumor-specific surface antigens are discovered and the linkage between genes and function is better understood, new targets will be identified for regulating tumor cell growth by engineered antibodies with agonist or antagonist activity. Additionally, antibody engineering will allow for more efficient radionuclide or cytotoxic drug targeting or lead to more selective activation of relevant host effector mechanisms, leading to a safe and effective therapy of cancer.
authors.affiliation: IDEC Pharmaceuticals Corporation, San Diego, CA 92191-9080, USA. mreff@idecpharm.com
authors.forename: M
authors.initials: M
authors.lastname: Reff
authors.forename: G
authors.initials: G
authors.lastname: Braslawsky
authors.forename: N
authors.initials: N
authors.lastname: Hanna
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006402:Hematologic Diseases / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D000922:Immunotoxins / Q000627:therapeutic use; D016499:Radioimmunotherapy
chemical_list: D000911:Antibodies, Monoclonal; D000922:Immunotoxins